Ventyx Biosciences
A biotechnology company with a diverse portfolio of best-in-class highly differentiated clinical and pre-clinical stage programs focused on high value targets.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor investor investor investor investor investor investor investor investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor investor investor investor investor | €0.0 Valuation: €0.0 -7.8x EV/EBITDA | round | |
| N/A | €0.0 | round | |
| investor investor investor investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
* | $27.0m | Post IPO Equity | |
| Total Funding | 000k | ||
| USD | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Ventyx Biosciences, Inc. operates as a clinical-stage biopharmaceutical firm, directing its efforts toward the development of selective, small molecule oral therapies for a range of autoimmune diseases. The company, which was founded in 2018, is headquartered in San Diego, California. Its establishment was the result of the merger of three companies: Oppilan Pharma, Zomagen Biosciences, and Ventyx, all of which were portfolio companies of New Science Ventures. This strategic consolidation brought together a diversified pipeline of clinical and preclinical assets aimed at immunology.
The company's business model is centered on identifying and advancing promising drug candidates through the various stages of clinical development. Ventyx targets the immunology and inflammation markets, developing treatments for conditions such as psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. Its revenue generation is prospective, contingent upon the successful commercialization of its product candidates or through strategic partnerships and licensing agreements with other pharmaceutical companies.
Ventyx's drug pipeline features several candidates. VTX958 is a tyrosine kinase 2 (TYK2) inhibitor being evaluated for the treatment of psoriasis, psoriatic arthritis, and Crohn's disease. Another key asset is VTX002, a sphingosine 1 phosphate receptor (S1P1R) modulator developed for patients with moderate-to-severe ulcerative colitis. The portfolio also includes VTX2735, a peripherally restricted NLRP3 inhibitor, and VTX3232, a CNS-penetrant NLRP3 inhibitor, targeting systemic and neuroinflammatory diseases. These molecules are designed to be taken orally, offering a potential convenience advantage over injectable biologics that currently dominate the market for many autoimmune disorders. In October 2021, Ventyx Biosciences successfully launched its initial public offering (IPO), raising approximately $174.3 million in gross proceeds to fund its research and development activities.
Keywords: biopharmaceutical, autoimmune diseases, immunology, oral therapies, clinical-stage, small molecule, TYK2 inhibitor, NLRP3 inhibitor, S1P1R modulator, inflammatory bowel disease